Daiichi Sankyo Korea’s HER2-positive breast cancer treatment ‘Enhertu (trastuzumab deruxteca); has raised sales of over KRW 7 billion in H1 this year without reimbursement.

According to the market research institution IQVIA on the 31st, Enhertu posted sales of KRW 7.4 billion in H1 this year, making KRW 2.2 billion in Q1 and KRW 5.2 billion in Q2.

Even without reimbursement listing, sales of the drug had exceeded KRW 7 billion. This indicates the many breast cancer patients in need of the treatment. The non-reimbursed cost of Enhertu is known to be in the KRW 5 million range per injection.

Enhertu is an antibody-drug conjugate (ADC) that was approved by the Ministry of